Test the efficacy of your compound(s) in a panel of 25 patient-derived organoids representing colorectal, pancreatic, and non-small cell lung cancer
enroll now
Our meticulously designed KRASmut panel was instrumental in developing the first-ever clinical candidate using organoid technology, targeting head & neck cancer
The Life Science business of Merck KGaA, Darmstadt, Germany Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
learn more
Please fill the form to receive a customised quote